| NB | Neuroblastoma |
| TIME | Tumor Immune Evasion |
| HR-NB | High-risk Neuroblastoma |
| NCC | Neural Crest Cells |
| TME | Tumor Microenvironment |
| TAMs | Tumor-associated Macrophages |
| MDSCs | Myeloid-Derived Suppressor Cells |
| Tc | T Lymphoid cells |
| DC | Dendritic Cells |
| NK | Natural Killer Cells |
| TDE | Tumor-Derived Exosomes |
| CT | Chemotherapy |
| RT | Radiotherapy |
| ASCT | Autologous Stem Cell Rescue |
| IMT | Incorporation of Immunotherapy |
| OS | Overall Survival |
| MRD | Minimal Residual Disease |
| MHC | Major Histocompatibility Complex |
| CSC | Cancer Stem Cell |
| scRNA-seq | Single Cell RNA Sequence |
| NO | Nitric Oxide |
| TCR | T Lymphoid cells Receptor |
| HIF | Hypoxia-Inducible Factor |
| CTL | Cytotoxic T Lymphocyte |
| APM | Antigen Processing Machinery |
| eAdo | Extracellular Adenosine |
| A2AR | A2A Adenosine Receptor |
| APCs | Antigen-Presenting Cells |
| Treg | T-regulatory cell |
| FAO | Fatty Acid Oxidation |
| OXPHOS | Oxidative Phosphorylation |
| GPX4 | Glutathione Peroxidase 4 |
| HDAC | Histone Deacetylase |
| HDACi | HDAC inhibitors |
| DNMT | DNA Methyltransferase |
| DNMTi | DNMT inhibitors |
| BET | Bromodomain and extraterminal domain |
| BETi | BET inhibitors |
| LSD1 | Lysine specific demethylase 1 |
| LSD1i | LSD1 inhibitors |
| PRC1 | Polycomb Repressive Complex 1 |
| HAT | Histone Acetyltransferase |
| PROTACs | Proteolysis-Targeting Chimeras |
| EVs | Extracellular Vehicles |
| MVB | Endosomal-Multivesicular Body |
| IL-2 | Interleukin-2 |
| PGE2 | Prostaglandin E2 |
| ARG1 | Arginase-1 |
| iNOS | Inducible Nitric Oxide Synthase |
| CSC-Exos | CSC-derived Exosomes |
| ADCC | Antibody-Dependent Cellular Cytotoxicity |
| CAR | Chimeric Antigen Receptor |
| NK-Exos | NK-cell-derived Exosomes |
| BsAbs | Bispecific Antibodies |
| Ovs | Oncolytic Viruses |